Aptose Biosciences, Inc. (APTO)
Stock Price:
$5.57 USD
-0.14 (-2.45%)
Updated Oct 20, 2020 10:27 AM EDT - Market open
Key Info
| Market Cap |
487.28M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-41.83M |
| Shares Out |
87.48M |
| EPS (ttm) |
-0.63 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$5.57 |
| Previous Close |
$5.71 |
| Change ($) |
-0.14 |
| Change (%) |
-2.45% |
| Day's Open |
5.73 |
| Day's Range |
5.56 - 5.75 |
| Day's Volume |
130,050 |
| 52-Week Range |
1.82 - 9.25 |
More Stats
| Market Cap |
487.28M |
| Enterprise Value |
405.87M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
87.48M |
| Float |
82.53M |
| EPS (basic) |
-0.61 |
| EPS (diluted) |
-0.63 |
| FCF / Share |
-0.35 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.53M |
| Short Ratio |
2.67 |
| Short % of Float |
3.07% |
| Beta |
0.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.31 |
| Revenue |
n/a |
| Operating Income |
-42.63M |
| Net Income |
-41.83M |
| Free Cash Flow |
-26.80M |
| Net Cash |
81.42M |
| Net Cash / Share |
0.93 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-43.14% |
| ROE |
-74.05% |
| ROIC |
-201.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.50*
(88.51% upside)
Low
9.00
Current: $5.57
High
13.00
Target: 10.50
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - | - |
| Operating Income | -26.86 | -29.11 | -11.83 | -14.27 | -12.86 | -10.33 | -5.59 | -4.60 |
| Net Income | -26.28 | -28.87 | -11.64 | -14.24 | -11.71 | -10.55 | -5.57 | -4.61 |
| Shares Outstanding | 50.16 | 33.39 | 22.31 | 12.74 | 11.91 | 5.22 | 3.52 | 1.69 |
| Earnings Per Share | -0.52 | -0.86 | -0.52 | -1.12 | -0.98 | -2.02 | -1.58 | -2.76 |
| Operating Cash Flow | -21.56 | -23.21 | -10.22 | -12.39 | -9.89 | -8.54 | -5.09 | -3.31 |
| Capital Expenditures | -0.10 | -0.33 | -0.01 | - | -0.26 | -0.02 | - | - |
| Free Cash Flow | -21.66 | -23.54 | -10.24 | -12.39 | -10.15 | -8.56 | -5.09 | -3.31 |
| Cash & Equivalents | 97.60 | 15.74 | 11.43 | 7.94 | 14.27 | 30.39 | 0.65 | - |
| Total Debt | 1.53 | - | - | - | - | 0.53 | - | - |
| Net Cash / Debt | 96.07 | 15.74 | 11.43 | 7.94 | 14.27 | 29.86 | 0.65 | - |
| Assets | 100 | 16.87 | 11.97 | 8.65 | 15.35 | 30.90 | 1.04 | - |
| Liabilities | 6.55 | 2.79 | 1.77 | 1.32 | 1.70 | 2.46 | 1.82 | - |
| Book Value | 93.93 | 14.08 | 10.20 | 7.33 | 13.65 | 28.44 | -0.78 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aptose Biosciences, Inc. |
| Country |
Canada |
| Employees |
31 |
| CEO |
William G. Rice |
Stock Information
| Ticker Symbol |
APTO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: APTO |
Description
Aptose Biosciences, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.